4:16 PM ET
8-K
Investor Presentation
Tenax Therapeutics Investor Presentation
Tenax Therapeutics filed an updated investor presentation detailing strategic changes to its Phase 3 LEVEL-2 clinical trial for TNX-103 in PH-HFpEF. The company is pausing enrollment to amend protocol criteria based on findings from its completed LEVEL trial and has requested a Type C meeting with the FDA to discuss the development path.